Arterial stiffness in diabetes mellitus

Atherosclerosis

Volumn 238, Issue 2, 2015, Pages 370-379

  Prenner, Stuart B ^a   Chirinos, Julio A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Arterial stiffness; Diabetes mellitus

Indexed keywords

ADVANCED GLYCATION END PRODUCT; NITRIC OXIDE; BIOLOGICAL MARKER; GLUCOSE BLOOD LEVEL;

ARTERIAL STIFFNESS; AUTONOMIC DYSFUNCTION; COGNITIVE DEFECT; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; HUMAN; IMPAIRED GLUCOSE TOLERANCE; METABOLIC SYNDROME X; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; ANIMAL; BLOOD; COMPLICATION; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE COURSE; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR;

ANIMALS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DISEASE PROGRESSION; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; NITRIC OXIDE; PROGNOSIS; RISK FACTORS; VASCULAR STIFFNESS;

EID: 84920911189     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.12.023     Document Type: Review

References (100)

1. Vlachopoulos C., Aznaouridis K., Stefanadis C. Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J.Am. Coll. Cardiol. 2010, 55:1318-1327.
2. Schram M.T., Henry R.M., van Dijk R.A., et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension 2004, 43:176-181.
3. Ohnishi H., Saitoh S., Takagi S., et al. Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: the Tanno and Sobetsu study. Diabetes Care 2003, 26:437-440.
4. Shin J.Y., Lee H.R., Lee D.C. Increased arterial stiffness in healthy subjects with high-normal glucose levels and in subjects with pre-diabetes. Cardiovasc. Diabetol. 2011, 10:30.
5. Fang F.S., Liu M.Y., Cheng X.L., et al. Insulin resistance correlates with the arterial stiffness before glucose intolerance. Intern. Med. 2014, 53:189-194.
6. Chirinos J.A., Segers P., Gillebert T.C., et al. Central pulse pressure and its hemodynamic determinants in middle-aged adults with impaired fasting glucose and diabetes: the Asklepios study. Diabetes Care 2013, 36:2359-2365.
7. Li C.H., Wu J.S., Yang Y.C., et al. Increased arterial stiffness in subjects with impaired glucose tolerance and newly diagnosed diabetes but not isolated impaired fasting glucose. J.Clin. Endocrinol. Metab. 2012, 97:E658-E662.
8. Li S., Chen W., Srinivasan S.R., et al. Influence of metabolic syndrome on arterial stiffness and its age-related change in young adults: the Bogalusa Heart Study. Atherosclerosis 2005, 180:349-354.
9. Safar M.E., Thomas F., Blacher J., et al. Metabolic syndrome and age-related progression of aortic stiffness. J.Am. Coll. Cardiol. 2006, 47:72-75.
10. Tomiyama H., Hirayama Y., Hashimoto H., et al. The effects of changes in the metabolic syndrome detection status on arterial stiffening: a prospective study. Hypertens. Res. Off. J. Jpn. Soc. Hypertens. 2006, 29:673-678.
11. Nakanishi N., Suzuki K., Tatara K. Clustered features of the metabolic syndrome and the risk for increased aortic pulse wave velocity in middle-aged Japanese men. Angiology 2003, 54:551-559.
12. Pietri P., Vlachopoulos C., Vyssoulis G., et al. Macro- and microvascular alterations in patients with metabolic syndrome: sugar makes the difference. Hypertens. Res. Off. J. Jpn. Soc. Hypertens. 2014, 37:452-456.
13. Sweitzer N.K., Shenoy M., Stein J.H., et al. Increases in central aortic impedance precede alterations in arterial stiffness measures in type 1 diabetes. Diabetes Care 2007, 30:2886-2891.
14. Brooks B., Molyneaux L., Yue D.K. Augmentation of central arterial pressure in type 1 diabetes. Diabetes Care 1999, 22:1722-1727.
15. Wilkinson I.B., MacCallum H., Rooijmans D.F., et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM Mon. J. Assoc. Physicians 2000, 93:441-448.
16. Gordin D., Ronnback M., Forsblom C., et al. Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes. Diabetologia 2007, 50:1808-1814.
17. Cameron J.D., Bulpitt C.J., Pinto E.S., et al. The aging of elastic and muscular arteries: a comparison of diabetic and nondiabetic subjects. Diabetes Care 2003, 26:2133-2138.
18. Safar M.E., Czernichow S., Blacher J. Obesity, arterial stiffness, and cardiovascular risk. J.Am. Soc. Nephrol. 2006, 17:S109-S111.
19. Cruickshank K., Riste L., Anderson S.G., et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?. Circulation 2002, 106:2085-2090.
20. Kimoto E., Shoji T., Shinohara K., et al. Regional arterial stiffness in patients with type 2 diabetes and chronic kidney disease. J.Am. Soc. Nephrol. 2006, 17:2245-2252.
21. Taniwaki H., Kawagishi T., Emoto M., et al. Correlation between the intima-media thickness of the carotid artery and aortic pulse-wave velocity in patients with type 2 diabetes. Vessel wall properties in type 2 diabetes. Diabetes Care 1999, 22:1851-1857.
22. Ravikumar R., Deepa R., Shanthirani C., et al. Comparison of carotid intima-media thickness, arterial stiffness, and brachial artery flow mediated dilatation in diabetic and nondiabetic subjects (The Chennai Urban Population Study [CUPS-9]). Am. J. Cardiol. 2002, 90:702-707.
23. Cockcroft J.R., Wilkinson I.B., Evans M., et al. Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus. Am. J. Hypertens. 2005, 18:1463-1467. discussion 1468-1469.
24. Schram M.T., Chaturvedi N., Fuller J.H., et al. Pulse pressure is associated with age and cardiovascular disease in type 1 diabetes: the Eurodiab Prospective Complications Study. J.Hypertens. 2003, 21:2035-2044.
25. van Dijk R.A., Dekker J.M., Nijpels G., et al. Brachial artery pulse pressure and common carotid artery diameter: mutually independent associations with mortality in subjects with a recent history of impaired glucose tolerance. Eur. J. Clin. Investig. 2001, 31:756-763.
26. Schram M.T., Kostense P.J., Van Dijk R.A., et al. Diabetes, pulse pressure and cardiovascular mortality: the Hoorn Study. J.Hypertens. 2002, 20:1743-1751.
27. Chirinos J.A., Kips J.G., Roman M.J., et al. Ethnic differences in arterial wave reflections and normative equations for augmentation index. Hypertension 2011, 57:1108-1116.
28. Cecelja M., Chowienczyk P. Dissociation of aortic pulse wave velocity with risk factors for cardiovascular disease other than hypertension: a systematic review. Hypertension 2009, 54:1328-1336.
29. De Angelis L., Millasseau S.C., Smith A., et al. Sex differences in age-related stiffening of the aorta in subjects with type 2 diabetes. Hypertension 2004, 44:67-71.
30. Dinneen S.F., Gerstein H.C. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. A systematic overview of the literature. Arch. Intern. Med. 1997, 157:1413-1418.
31. Molitch M.E., Steffes M., Sun W., et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care 2010, 33:1536-1543.
32. Yokoyama H., Aoki T., Imahori M., et al. Subclinical atherosclerosis is increased in type 2 diabetic patients with microalbuminuria evaluated by intima-media thickness and pulse wave velocity. Kidney Int. 2004, 66:448-454.
33. Yokoyama H., Hirasawa K., Aoki T., et al. Brachial-ankle pulse wave velocity measured automatically by oscillometric method is elevated in diabetic patients with incipient nephropathy. Diabet. Med. J. Br. Diabet. Assoc. 2003, 20:942-945.
34. Smith A., Karalliedde J., De Angelis L., et al. Aortic pulse wave velocity and albuminuria in patients with type 2 diabetes. J.Am. Soc. Nephrol. 2005, 16:1069-1075.
35. Ishimura E., Taniwaki H., Tsuchida T., et al. Urinary albumin excretion associated with arterial wall stiffness rather than thickness in type 2 diabetic patients. J.Nephrol. 2007, 20:204-211.
36. Aoun S., Blacher J., Safar M.E., et al. Diabetes mellitus and renal failure: effects on large artery stiffness. J.Hum. Hypertens. 2001, 15:693-700.
37. Bouchi R., Babazono T., Mugishima M., et al. Arterial stiffness is associated with incident albuminuria and decreased glomerular filtration rate in type 2 diabetic patients. Diabetes Care 2011, 34:2570-2575.
38. Pannier B., Guerin A.P., Marchais S.J., et al. Stiffness of capacitive and conduit arteries: prognostic significance for end-stage renal disease patients. Hypertension 2005, 45:592-596.
39. Pedrinelli R., Dell'Omo G., Penno G., et al. Microalbuminuria and pulse pressure in hypertensive and atherosclerotic men. Hypertension 2000, 35:48-54.
40. Oliveras A., Garcia-Ortiz L., Segura J., et al. Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. J.Hypertens. 2013, 31:103-108.
41. Farasat S.M., Valdes C., Shetty V., et al. Is longitudinal pulse pressure a better predictor of 24-hour urinary albumin excretion than other indices of blood pressure?. Hypertension 2010, 55:415-421.
42. Fogo A., Breyer J.A., Smith M.C., et al. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: a report from the African American Study of Kidney Disease (AASK) Trial. AASK Pilot Study Investigators. Kidney Int. 1997, 51:244-252.
43. Juutilainen A., Lehto S., Ronnemaa T., et al. Retinopathy predicts cardiovascular mortality in type 2 diabetic men and women. Diabetes Care 2007, 30:292-299.
44. Targher G., Bertolini L., Zenari L., et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in type 2 diabetic patients. Diabet. Med. J. Br. Diabet. Assoc. 2008, 25:45-50.
45. Kim W.J., Park C.Y., Park S.E., et al. The association between regional arterial stiffness and diabetic retinopathy in type 2 diabetes. Atherosclerosis 2012, 225:237-241.
46. Yun Y.W., Shin M.H., Lee Y.H., et al. Arterial stiffness is associated with diabetic retinopathy in Korean type 2 diabetic patients. J.Prev. Med. Public Health/Yebang Uihakhoe chi 2011, 44:260-266.
47. Ogawa O., Hiraoka K., Watanabe T., et al. Diabetic retinopathy is associated with pulse wave velocity, not with the augmentation index of pulse waveform. Cardiovasc. Diabetol. 2008, 7:11.
48. Ogawa O., Hayashi C., Nakaniwa T., et al. Arterial stiffness is associated with diabetic retinopathy in type 2 diabetes. Diabetes Res. Clin. Pract. 2005, 68:162-166.
49. Tanaka K., Kawai T., Saisho Y., et al. Relationship between stage of diabetic retinopathy and pulse wave velocity in Japanese patients with type 2 diabetes. J.Diabetes Res. 2013, 2013:193514.
50. Rema M., Mohan V., Deepa R., et al. Association of carotid intima-media thickness and arterial stiffness with diabetic retinopathy: the Chennai Urban Rural Epidemiology Study (CURES-2). Diabetes Care 2004, 27:1962-1967.
51. Ewing D.J., Campbell I.W., Clarke B.F. The natural history of diabetic autonomic neuropathy. Q.J. Med. 1980, 49:95-108.
52. Chen H.S., Hwu C.M., Kuo B.I., et al. Abnormal cardiovascular reflex tests are predictors of mortality in type 2 diabetes mellitus. Diabet. Med. J. Br. Diabet. Assoc. 2001, 18:268-273.
53. Zander E., Schulz B., Heinke P., et al. Importance of cardiovascular autonomic dysfunction in IDDM subjects with diabetic nephropathy. Diabetes Care 1989, 12:259-264.
54. Krolewski A.S., Barzilay J., Warram J.H., et al. Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Diabetes 1992, 41:430-437.
55. Spallone V., Gambardella S., Maiello M.R., et al. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. Diabetes Care 1994, 17:578-584.
56. Meyer C., Milat F., McGrath B.P., et al. Vascular dysfunction and autonomic neuropathy in type 2 diabetes. Diabet. Med. J. Br. Diabet. Assoc. 2004, 21:746-751.
57. Theilade S., Lajer M., Persson F., et al. Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes. Diabetes Care 2013, 36:715-721.
58. Park B.J., Lee H.R., Shim J.Y., et al. Association between resting heart rate and arterial stiffness in Korean adults. Arch. Cardiovasc. Dis. 2010, 103:246-252.
59. Ha B.K., Kim B.G., Kim D.H., et al. Relationships between brachial-ankle pulse wave velocity and peripheral neuropathy in type 2 diabetes. Diabetes Metab. J. 2012, 36:443-451.
60. Suh B.C., Chung P.W., Moon H.S., et al. Association between pulse wave velocity and nerve conduction study in diabetic patients. Eur. Neurol. 2010, 64:219-223.
61. Yokoyama H., Yokota Y., Tada J., et al. Diabetic neuropathy is closely associated with arterial stiffening and thickness in type 2 diabetes. Diabet. Med. J. Br. Diabet. Assoc. 2007, 24:1329-1335.
62. Cardoso C.R., Ferreira M.T., Leite N.C., et al. Microvascular degenerative complications are associated with increased aortic stiffness in type 2 diabetic patients. Atherosclerosis 2009, 205:472-476.
63. Tanaka M., Babazono T., Takeda M., et al. Pulse pressure and chronic kidney disease in patients with type 2 diabetes. Hypertens. Res. Off. J. Jpn. Soc. Hypertens. 2006, 29:345-352.
64. Knudsen S.T., Poulsen P.L., Hansen K.W., et al. Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetes. Am. J. Hypertens. 2002, 15:244-250.
65. Laugesen E., Hoyem P., Stausbol-Gron B., et al. Carotid-femoral pulse wave velocity is associated with cerebral white matter lesions in type 2 diabetes. Diabetes Care 2013, 36:722-728.
66. Ogawa O., Onuma T., Kubo S., et al. Brachial-ankle pulse wave velocity and symptomatic cerebral infarction in patients with type 2 diabetes: a cross-sectional study. Cardiovasc. Diabetol. 2003, 2:10.
67. Mehrabian S., Raycheva M., Gateva A., et al. Cognitive dysfunction profile and arterial stiffness in type 2 diabetes. J.Neurol. Sci. 2012, 322:152-156.
68. Sell D.R., Monnier V.M. Molecular basis of arterial stiffening: role of glycation - a mini-review. Gerontology 2012, 58:227-237.
69. Meerwaldt R., Links T., Zeebregts C., et al. The clinical relevance of assessing advanced glycation endproducts accumulation in diabetes. Cardiovasc. Diabetol. 2008, 7:29.
70. Tessier F.J. The Maillard reaction in the human body. The main discoveries and factors that affect glycation. Pathol. Biol. 2010, 58:214-219.
71. Prasad A., Bekker P., Tsimikas S. Advanced glycation end products and diabetic cardiovascular disease. Cardiol. Rev. 2012, 20:177-183.
72. Baynes J.W., Thorpe S.R. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 1999, 48:1-9.
73. Brownlee M., Vlassara H., Kooney A., et al. Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science 1986, 232:1629-1632.
74. International Expert, C International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009, 32:1327-1334.
75. Peters A.L., Davidson M.B., Schriger D.L., et al. Aclinical approach for the diagnosis of diabetes mellitus: an analysis using glycosylated hemoglobin levels. Meta-analysis Research Group on the Diagnosis of Diabetes Using Glycated Hemoglobin Levels. J.Am. Med. Assoc. 1996, 276:1246-1252.
76. Koenig R.J., Peterson C.M., Jones R.L., et al. Correlation of glucose regulation and hemoglobin AIc in diabetes mellitus. N.Engl. J. Med. 1976, 295:417-420.
77. Powell J.T., Vine N., Crossman M. On the accumulation of D-aspartate in elastin and other proteins of the ageing aorta. Atherosclerosis 1992, 97:201-208.
78. Schnider S.L., Kohn R.R. Effects of age and diabetes mellitus on the solubility and nonenzymatic glucosylation of human skin collagen. J.Clin. Investig. 1981, 67:1630-1635.
79. Monnier V.M., Vishwanath V., Frank K.E., et al. Relation between complications of type I diabetes mellitus and collagen-linked fluorescence. N.Engl. J. Med. 1986, 314:403-408.
80. Sims T.J., Rasmussen L.M., Oxlund H., et al. The role of glycation cross-links in diabetic vascular stiffening. Diabetologia 1996, 39:946-951.
81. Kawashima S. The two faces of endothelial nitric oxide synthase in the pathophysiology of atherosclerosis. Endothel. J. Endothel. Cell Res. 2004, 11:99-107.
82. Creager M.A., Luscher T.F., Cosentino F., et al. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part I. Circulation 2003, 108:1527-1532.
83. Du X., Edelstein D., Obici S., et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. J.Clin. Investig. 2006, 116:1071-1080.
84. Brillante D.G., O'Sullivan A.J., Johnstone M.T., et al. Arterial stiffness and haemodynamic response to vasoactive medication in subjects with insulin-resistance syndrome. Clin. Sci. 2008, 114:139-147.
85. Vehkavaara S., Seppala-Lindroos A., Westerbacka J., et al. Invivo endothelial dysfunction characterizes patients with impaired fasting glucose. Diabetes Care 1999, 22:2055-2060.
86. Avogaro A., Piarulli F., Valerio A., et al. Forearm nitric oxide balance, vascular relaxation, and glucose metabolism in NIDDM patients. Diabetes 1997, 46:1040-1046.
87. Brillante D.G., O'Sullivan A.J., Howes L.G. Arterial stiffness in insulin resistance: the role of nitric oxide and angiotensin II receptors. Vasc. Health Risk Manag. 2009, 5:73-78.
88. Kilhovd B.K., Juutilainen A., Lehto S., et al. Increased serum levels of advanced glycation endproducts predict total, cardiovascular and coronary mortality in women with type 2 diabetes: a population-based 18 year follow-up study. Diabetologia 2007, 50:1409-1417.
89. Nin J.W., Jorsal A., Ferreira I., et al. Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes Care 2011, 34:442-447.
90. Nin J.W., Jorsal A., Ferreira I., et al. Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study. Diabetes 2010, 59:2027-2032.
91. Schram M.T., Schalkwijk C.G., Bootsma A.H., et al. Advanced glycation end products are associated with pulse pressure in type 1 diabetes: the EURODIAB Prospective Complications Study. Hypertension 2005, 46:232-237.
92. Semba R.D., Najjar S.S., Sun K., et al. Serum carboxymethyl-lysine, an advanced glycation end product, is associated with increased aortic pulse wave velocity in adults. Am. J. Hypertens. 2009, 22:74-79.
93. Won K.B., Chang H.J., Park S.H., et al. High serum advanced glycation end-products predict coronary artery disease irrespective of arterial stiffness in diabetic patients. Korean Circ. J. 2012, 42:335-340.
94. Monnier V.M., Sell D.R., Genuth S. Glycation products as markers and predictors of the progression of diabetic complications. Ann. N. Y. Acad. Sci. 2005, 1043:567-581.
95. Webb D.R., Davies M.J., Gray L.J., et al. Searching for the right outcome? A systematic review and meta-analysis of controlled trials using carotid intima-media thickness or pulse wave velocity to infer antiatherogenic properties of thiazolidinediones. Diabetes Obes. Metab. 2010, 12:124-132.
96. Nesto R.W., Bell D., Bonow R.O., et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation October 7, 2003, 2003(108):2941-2948.
97. O'Rourke M.F., Hashimoto J. Mechanical factors in arterial aging: a clinical perspective. J.Am. Coll. Cardiol. 2007, 50:1-13.
98. Ford M.L., Tomlinson L.A., Chapman T.P., et al. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 2010, 55:1110-1115.
99. Yasuno S., Ueshima K., Oba K., et al. Is pulse pressure a predictor of new-onset diabetes in high-risk hypertensive patients?: A subanalysis of the Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial. Diabetes Care 2010, 33:1122-1127.
100. Anan F., Masaki T., Eto T., et al. Postchallenge plasma glucose and glycemic spikes are associated with pulse pressure in patients with impaired glucose tolerance and essential hypertension. Hypertens. Res. Off. J. Jpn. Soc. Hypertens. 2008, 31:1565-1571.